Molecular Devices Introduces SpectraMax(R) M5 Multi-Detection Microplate Reader System
October 25 2004 - 5:30PM
PR Newswire (US)
Molecular Devices Introduces SpectraMax(R) M5 Multi-Detection
Microplate Reader System SUNNYVALE, Calif., Oct. 25
/PRNewswire-FirstCall/ -- Molecular Devices Corporation
(NASDAQ:MDCC) today announced the introduction of SpectraMax(R) M5,
a five-mode multi-detection microplate reader system, and the
latest addition to the company's popular SpectraMax product line.
The system has primary applications for fluorescence intensity,
absorbance, luminescence, Time-Resolved Fluorescence (TRF) and
Fluorescence Polarization (FP) assays, and will debut today at
Neuroscience 2004 in San Diego, California. The SpectraMax M5 will
allow life science and drug discovery researchers to increase their
productivity by giving them multiple detection modes in one
powerful, compact instrument. The SpectraMax M5 features a
triple-mode cuvette port and a single-read command capability for
experiments requiring multiple detection parameters. The system
also gives users the flexibility to choose wavelengths between 200
nm and 1000 nm. The SpectraMax M5 uses standard microplates to read
endpoint, kinetic, spectrum, multi-wavelength and well-area
scanning. For life sciences research, the system is well suited for
ELISA, nucleic acid, protein quantitation, enzymatic, cell
viability and proliferation assays. Kinase, reporter gene, FRET and
other homogeneous and heterogeneous assays can also be run.
Commenting on the launch, Stephen J. Oldfield, Ph.D., Molecular
Devices' Vice President of Worldwide Marketing, stated, "The
SpectraMax M5 has optical performance which is comparable to our
dedicated, top-of-the-line readers for all five of its primary
detection modes. With its broad assay capability, this system can
be used as a research tool to optimize assays in early ADME or
quality control, or used as a screening instrument." He further
stated, "When the SpectraMax M5 is integrated with our
SynchroMax(TM) ET plate handling robot, up to 320 plates can be run
without interruption, with multiple assay parameters on each
plate." SpectraMax M5 utilizes SoftMax(R) Pro Enterprise software,
the industry- leading data acquisition and analysis software with
FDA 21 CFR Part 11 compliance tools. Molecular Devices Corporation
is a leading supplier of high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life
sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in
genomics, proteomics and combinatorial chemistry by facilitating
the high- throughput and cost-effective identification and
evaluation of drug candidates. The Company's solutions are based on
its advanced core technologies that integrate its expertise in
engineering, molecular and cell biology and chemistry. Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of
discovering and developing new drugs. This press release contains
"forward-looking" statements, including statements related to the
prospects for or potential customer use of the SpectraMax(R) M5.
Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "will," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause the results of Molecular Devices Corporation to
differ materially from those indicated by these forward-looking
statements, including, among others, risks related to the
development of new products and other risks detailed from time to
time in the Company's SEC reports, including its Annual Report on
Form 10-K for the year ended December 31, 2003, as amended, and its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.
Molecular Devices Corporation does not undertake any obligation to
update forward-looking statements. DATASOURCE: Molecular Devices
Corporation CONTACT: Tim Harkness of Molecular Devices Corporation,
+1-408-747-3533 Web site: http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024